SynthesisBiomolecules & biomedicine2025
Atherogenic index of plasma and risk of diabetic nephropathy in type 2 diabetes: A meta‑analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses.BMC cardiovascular disorders · 2025Pooled it
- Objective tongue phenotyping identifies phenotypic heterogeneity in diabetic kidney disease: a dual-center clustering analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The atherogenic index of plasma (AIP) is a lipid-based biomarker associated with cardiovascular and renal risks in individuals with type 2 diabetes mellitus (T2DM). However, its relationship with diabetic nephropathy (DN) remains inadequately defined. This meta-analysis aims to assess the association between AIP and DN in T2DM patients. We conducted a comprehensive search in PubMed, Embase, and Web of Science for observational studies that compared the incidence or prevalence of DN across varying AIP levels in T2DM populations. Data were synthesized using a random-effects model to account for potential heterogeneity. A total of eleven datasets from ten studies, encompassing 25,773 T2DM patients, were included in the analysis. The pooled results indicated that higher AIP levels are significantly associated with DN (risk ratio [RR] = 1.51, 95% confidence interval [CI]: 1.36-1.67; p < 0.001). Subgroup analyses revealed a stronger association in patients aged 58 years or older (RR = 1.66) compared to those younger than 58 years (RR = 1.35; p for subgroup difference = 0.02). Similar associations were observed across different study designs, sex distributions, AIP cutoff values, definitions of DN, and quality scores (p for subgroup difference all > 0.05). Meta-regression analysis further indicated that older age positively influenced the strength of the association (coefficient = 0.018, p = 0.03). In conclusion, elevated AIP levels are significantly associated with diabetic nephropathy in T2DM patients, particularly among older individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.